Physiological role of naturally-occuring amyloid beta oligomers
Physiological role of naturally-occuring amyloid beta oligomers
批准号:
9759747
负责人:
WILLIAM L KLEIN
金额:
$19.29万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2018
资助国家:
美国
项目状态:
已结题
起止时间:
2018-08-15 至 2021-05-31
关键词:
AddressAdultAlzheimer&aposs DiseaseAmino Acid SequenceAmyloid beta-ProteinAnimal ModelAnimalsBiologyBrainBrain DiseasesChickensDangerousnessDementiaDevelopmentDiseaseEmbryoEtiologyEvolutionExperimental ModelsEye diseasesGlaucomaHomoHumanImmunohistochemistryIn VitroLinkMacular degenerationMemory impairmentMicrogliaModelingNatureNeurologicOryctolagus cuniculusPathogenicityPathologicPathologyPatternPeptidesPhysiologicalRegulationRetinaRoleSerineSiteSynapsesTestingTherapeuticTimeWestern Blottingabeta oligomerbrain tissuecellular developmentexperimental studyganglion cellhuman modelinsightnanomolarneuroinflammationneuron lossneuropathologynon-dementednonhuman primaterelating to nervous systemselective expressionsynaptic pruningtau Proteinstau phosphorylationtau-1
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Surprisingly, evolution has retained an amino acid sequence for the human Aβ42 peptide that favors formation
of large homo-oligomers. It is widely regarded that these unusual molecules are pathogenic. These oligomers
accumulate in human and animal model brain tissue in an Alzheimer's disease-dependent manner. They have
been shown experimentally to impact the CNS in a manner that causes memory dysfunction and recapitulates
AD neuropathology (e.g., tau hyperphosphorylation, neuroinflammation, synapse loss, selective nerve cell
death). Pathological AβO buildup begins early in the disease, before plaques, but it is not evident in healthy,
non-demented adults. In vitro, toxic AβOs readily assemble from nanomolar concentrations of synthetic human
Aβ. The same oligomer-forming sequence is found in certain animal species (e.g., nonhuman primates, rabbit,
chicken, but not rodents). It is peculiar that these species have retained the apparently dangerous capacity to
form molecules that instigate the neural damage leading to AD dementia. The current project addresses the
possibility that circumstances exist whereupon AβOs manifest a functional, physiological presence. In the long-
run, determining such circumstances is expected to give a significantly new perspective into the triggers and
mechanisms of toxic AβO buildup in AD. The working hypothesis tested is that AβOs have a transient, functional
role during CNS development, a possibility strongly supported by preliminary findings. Western blots and
immunohistochemistry show the presence of AβOs in the developing chick, whose Aβ sequence is the same as
humans. AβOs in embryonic retina are selectively expressed by ganglion cells, which, somewhat remarkably,
likewise show a presence of tau phosphorylated at the AD serine-396 site. Nothing is known about the function
of the developmentally-regulated AβOs, but it is feasible that the developmental impact may resemble the
pathological impact observed in adult brain. Looked at another way, when AβOs re-emerge pathologically in
adults, they impact brain tissue in a manner re-capitulating developmental functions. Developmental functions
of AβOs thus might comprise, e.g., stimulation of tau hyperphosphorylation, microgliosis, synaptic pruning or
selective nerve cell death. The Aims test the hypothesis using developing chick retina for experimentation.
Aim 1 Determine the onset, peak expression and disappearance pattern for particular AβO species relative
to AD-like tau hyperphosphorylation and microglial differentiation during retina development.
Aim 2 Determine the influence that transient AβOs exert on cellular development of retina, particularly with
respect to microglia and tau hyperphosphorylation.
Results are expected to establish that Alzheimer's-related AβOs serve a physiological role during development.
Embryonic chick will be introduced as an exceptionally well-suited model for investigating the regulation of AβO
expression and normal AβO function, including its relationship to tau and microglia. By achieving the first insights
into normal AβO biology, it is expected that new and deeper insight into AβO pathobiology will be achieved.
期刊论文(1)
专著(0)
科研奖励(0)
会议论文
DOI:
10.3390/ijms23042208
发表时间:
2022-02-17
期刊:
International journal of molecular sciences
影响因子:
5.6
作者:
[Bartley SC, Proctor MT, Xia H, Ho E, Kang DS, Schuster K, Bicca MA, Seckler HS, Viola KL, Patrie SM, Kelleher NL, De Mello FG, Klein WL]
通讯作者:
Klein WL
Development of a non-fibrillic amyloid-beta oligomer selective positron emission tomography imaging diagnostic for Alzheimer.
-
批准号:9202960
-
项目类别:
-
资助金额:$22.22万
-
财政年份:2016
-
负责人:WILLIAM L KLEIN
-
依托单位:
A novel, nanoparticle-based molecular MRI probe for early Alzheimer's diagnostics
-
批准号:8842908
-
项目类别:
-
资助金额:$18.73万
-
财政年份:2014
-
负责人:WILLIAM L KLEIN
-
依托单位:
A novel, nanoparticle-based molecular MRI probe for early Alzheimer's diagnostics
-
批准号:8683797
-
项目类别:
-
资助金额:$23.18万
-
财政年份:2014
-
负责人:WILLIAM L KLEIN
-
依托单位:
Alzheimer's Drug Discovery Using Unique Nanotechnology Platform
-
批准号:8548221
-
项目类别:
-
资助金额:$18.44万
-
财政年份:2012
-
负责人:WILLIAM L KLEIN
-
依托单位:
Alzheimer's Drug Discovery Using Unique Nanotechnology Platform
-
批准号:8446087
-
项目类别:
-
资助金额:$24.74万
-
财政年份:2012
-
负责人:WILLIAM L KLEIN
-
依托单位:
ADDLs, synapses & the molecular etiology of Alzheimer's disease
-
批准号:7615522
-
项目类别:
-
资助金额:$30.34万
-
财政年份:2007
-
负责人:WILLIAM L KLEIN
-
依托单位:
ADDLs, synapses & the molecular etiology of Alzheimer's disease
-
批准号:7184209
-
项目类别:
-
资助金额:$30.96万
-
财政年份:2007
-
负责人:WILLIAM L KLEIN
-
依托单位:
ADDLs, synapses & the molecular etiology of Alzheimer's disease
-
批准号:7470605
-
项目类别:
-
资助金额:$30.34万
-
财政年份:2007
-
负责人:WILLIAM L KLEIN
-
依托单位:
Abeta oligomers (ADDLs) in Alzheimers Disease pathology
-
批准号:6678227
-
项目类别:
-
资助金额:$33.05万
-
财政年份:2003
-
负责人:WILLIAM L KLEIN
-
依托单位:
Abeta oligomers (ADDLs) in Alzheimer's Disease pathology
-
批准号:7805554
-
项目类别:
-
资助金额:$30.65万
-
财政年份:2003
-
负责人:WILLIAM L KLEIN
-
依托单位:
Abeta oligomers (ADDLs)in Alzheimers Disease pathology
-
批准号:6931646
-
项目类别:
-
资助金额:$34.61万
-
财政年份:2003
-
负责人:WILLIAM L KLEIN
-
依托单位:
Abeta oligomers (ADDLs) in Alzheimer's Disease pathology
-
批准号:7467169
-
项目类别:
-
资助金额:$30.96万
-
财政年份:2003
-
负责人:WILLIAM L KLEIN
-
依托单位:
Abeta oligomers (ADDLs)in Alzheimers Disease pathology
-
批准号:6795925
-
项目类别:
-
资助金额:$34.62万
-
财政年份:2003
-
负责人:WILLIAM L KLEIN
-
依托单位:
Abeta oligomers (ADDLs) in Alzheimer's Disease pathology
-
批准号:7595791
-
项目类别:
-
资助金额:$30.96万
-
财政年份:2003
-
负责人:WILLIAM L KLEIN
-
依托单位:
NEUROLOGICAL DEFICITS DUE TO TOXIC A BETA OLIGOMERS
-
批准号:6233462
-
项目类别:
-
资助金额:$30.45万
-
财政年份:2001
-
负责人:WILLIAM L KLEIN
-
依托单位:
NEUROLOGICAL DEFICITS DUE TO TOXIC A BETA OLIGOMERS
-
批准号:6615732
-
项目类别:
-
资助金额:$29.23万
-
财政年份:2001
-
负责人:WILLIAM L KLEIN
-
依托单位:
NEUROLOGICAL DEFICITS DUE TO TOXIC A BETA OLIGOMERS
-
批准号:6532552
-
项目类别:
-
资助金额:$29.31万
-
财政年份:2001
-
负责人:WILLIAM L KLEIN
-
依托单位:
MORPHOGENIC SIGNAL TRANSDUCTION IN NEURONS
-
批准号:2703069
-
项目类别:
-
资助金额:$19.22万
-
财政年份:1996
-
负责人:WILLIAM L KLEIN
-
依托单位:
MORPHOGENIC SIGNAL TRANSDUCTION IN NEURONS
-
批准号:2273680
-
项目类别:
-
资助金额:$18.86万
-
财政年份:1996
-
负责人:WILLIAM L KLEIN
-
依托单位:
MORPHOGENIC SIGNAL TRANSDUCTION IN NEURONS
-
批准号:2416394
-
项目类别:
-
资助金额:$18.61万
-
财政年份:1996
-
负责人:WILLIAM L KLEIN
-
依托单位:
海外基金